Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
IGR-H82E3 | Human | Biotinylated Human IGF-I R / CD221 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
IGR-H5229 | Human | Human IGF-I R / CD221 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
IGR-C5225 | Cynomolgus | Cynomolgus IGF-I R / CD221 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
IGR-R5224 | Rat | Rat IGF-I R / CD221 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
IGR-M5223 | Mouse | Mouse IGF-I R / CD221 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
Biotinylated Human IGF-I R, His,Avitag (Cat. No. IGR-H82E3) immobilized on CM5 Chip can bind Human IGF-I, His Tag (Cat. No. IG1-H5245) with an affinity constant of 33.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
IGF-1 (Biogen/Pharmacia & Upjohn) | Approved | Biogen Inc, Pharmacia & Upjohn | Igef | Sweden | Dwarfism | null | 1994-01-01 | Dwarfism | Details | |
Mecasermin (Astellas/OrphanPacific) | Approved | Astellas Pharma Inc | Somazon | Japan | Dwarfism; Diabetes Mellitus, Lipoatrophic; Growth hormone deficiency | null | 1994-10-05 | Diabetes Mellitus, Lipoatrophic; Dwarfism; Growth hormone deficiency | Details | |
Mecasermin (Ipsen) | IGF-1; FK-780; MKN-031 | Approved | Ipsen | Increlex | EU | Laron Syndrome | Ipsen Pharma | 2005-08-30 | Failure to Thrive; Growth Disorders; Laron Syndrome | Details |
Ceritinib | LDK-378; NVP-LDK378; NVP-LDK378-NX | Approved | Novartis Pharma Ag | 赞可达, Zykadia | Mainland China | Carcinoma, Non-Small-Cell Lung | Novartis Europharm Ltd | 2014-04-29 | Stomach Neoplasms; Glioblastoma; Pancreatic Neoplasms; Adenocarcinoma of Lung; Cholangiocarcinoma; Colorectal Neoplasms; Hepatic Insufficiency; Carcinoma, Squamous Cell; Lymphoma, Large-Cell, Anaplastic; Granuloma, Plasma Cell; Esophageal adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
Teprotumumab | R-1507; RG-1507; RO-4858696; HZN-001 | Approved | Genmab, F. Hoffmann-La Roche Ltd | Tepezza | United States | Graves Ophthalmopathy | Horizon Therapeutics Ireland | 2020-01-21 | Graves Ophthalmopathy; Diabetic macular oedema; Sarcoma; Breast Neoplasms; Prostatic Neoplasms; Scleroderma, Diffuse | Details |
Brigatinib | AP-26113 | Approved | Takeda Pharmaceutical Co Ltd, Ariad | Alunbrig | Japan | Carcinoma, Non-Small-Cell Lung | Takeda | 2017-04-28 | Solid tumours; Carcinoma; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
VPI-2690B | VPI-2690B | Phase 2 Clinical | University Of North Carolina At Chapel Hill | Diabetic Nephropathies | Details |
BIIB-022 | BIIB-022 | Phase 1 Clinical | Biogen Inc | Solid tumours; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
BVS-857 | BVS-857 | Phase 2 Clinical | Novartis Pharma Ag | Insulin Resistance; Bulbo-Spinal Atrophy, X-Linked | Details |
Conteltinib | CT-707; SY-707 | Phase 3 Clinical | Shouyao Holding (Beijing) Co Ltd, Centaurus Biopharma Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
Picropodophyllin | PPP; AXL-1717; NSC-36407 | Phase 2 Clinical | Axelar Ab | Astrocytoma; Carcinoma, Non-Small-Cell Lung | Details |
W-0101 (Pierre Fabre Medicament) | W-0101 | Phase 2 Clinical | Pierre Fabre Group | Solid tumours | Details |
124I-CPD-1023-figitumumab | 124I-CPD-1028; 125I-CPD-1028; CPD-1028-[124I]; CPD-1028-[125I]; FPX-1028 | Phase 1 Clinical | Fusion Pharma | Neoplasms | Details |
CT-102 | CT-102 | Phase 1 Clinical | Hangzhou Tianlong Pharmaceutical Co Ltd, Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences | Carcinoma, Hepatocellular | Details |
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) | Phase 1 Clinical | Sidney Kimmel Cancer Center | Glioma | Details | |
Insulin-Like Growth Factor 1 (Wright State Physicians) | Phase 1 Clinical | Wright State Physicians | Nasolabial fold wrinkles; Sunburn | Details | |
Dalotuzumab | h7C-10; MK-0646; F-50-035 | Phase 2 Clinical | Pierre Fabre Group | Solid tumours; Rectal Neoplasms; Pancreatic Neoplasms; Multiple Myeloma; Neuroendocrine Tumors; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
IGV-001 | IGV-001 | Phase 2 Clinical | Thomas Jefferson University | Glioblastoma | Details |
INSM-18 | INS-18; TT-100; INSM-18 | Phase 1 Clinical | Insmed | Idiopathic Pulmonary Fibrosis; Prostatic Neoplasms | Details |
VRDN-001 | VRDN-001 | Phase 2 Clinical | Viridian Therapeutics Inc | Solid tumours; Multiple Myeloma; Graves Ophthalmopathy; Breast Neoplasms | Details |
Ganitumab | AMG-479 | Phase 3 Clinical | Amgen Inc | Sarcoma, Ewing; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Neoplasm Metastasis; Lung Neoplasms; Lymphoma; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Solid tumours; Sarcoma; Small Cell Lung Carcinoma; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoid Tumor; Rectal Neoplasms; Ovarian Neoplasms; Intestinal Neoplasms | Details |
Mecasermin Rinfabate | OHB-607; SHP-607; HGT-ROP-001; rhIGF-I/rhIGFBP-3; TAK-607 | Phase 2 Clinical | Insmed | Noonan Syndrome; Failure to Thrive; Cerebral Intraventricular Hemorrhage; Bronchopulmonary Dysplasia; Retinopathy of Prematurity; Laron Syndrome; Muscular Dystrophies | Details |
This web search service is supported by Google Inc.